Limits the substitution of abuse-deterrent analgesic opioid drug products for analgesic opioids lacking such technology
Summary
Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.
Bill status
in committee
1 of 4 stages cleared
Introduction
Apr 2021
Committee Review
Floor Vote
Governor
Introduced Apr 13, 2021
Last action Jan 5, 2022
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
2
Jan 5, 2022
Committee
REFERRED TO INSURANCE
upper
Apr 13, 2021
Committee
REFERRED TO INSURANCE
upper
1 primary · 0 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Andrew Lanza
RRepublican/Conservative/Independence/Reform
Ask Maddy
·
AI policy assistant
Ask Maddy about S 6180
Scope: NY
Hi! I can help you understand S 6180. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline